And yet, in a strange way, the PRs, while perhaps

And yet, in a strange way, the PRs, while perhaps not as well written as some would like, reflect a good bit of activity going on...peptide results yet to be announced but anticipated soon (along with FDA feedback by next week)...overseas arrangements of one sort or another in China and Malaysia, additional funding arrangements, movement with Altucell and Arizona...and more that I’ve forgotten. They are going through the doorways that are open to them right now. Like or dislike Joe, they seem to be very busy trying to build something of value for GNBT shareholders. I’m giving them props for that.